These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

48 related items for PubMed ID: 17436590

  • 1. Efficient dual treatment of the hormone-refractory prostate cancer cell line DU145 with cetuximab and 1,25-dihydroxyvitamin D3.
    Belochitski O, Ariad S, Shany S, Fridman V, Gavrilov V.
    In Vivo; 2007; 21(2):371-6. PubMed ID: 17436590
    [Abstract] [Full Text] [Related]

  • 2. The combined treatment of 1,25-dihydroxyvitamin D3 and a non-steroid anti-inflammatory drug is highly effective in suppressing prostate cancer cell line (LNCaP) growth.
    Gavrilov V, Steiner M, Shany S.
    Anticancer Res; 2005; 25(5):3425-9. PubMed ID: 16101159
    [Abstract] [Full Text] [Related]

  • 3. Regulation of epidermal growth factor receptor levels by 1,25-dihydroxyvitamin D3 in human breast cancer cells.
    Koga M, Eisman JA, Sutherland RL.
    Cancer Res; 1988 May 15; 48(10):2734-9. PubMed ID: 2834048
    [Abstract] [Full Text] [Related]

  • 4. The iroquois homeobox gene 5 is regulated by 1,25-dihydroxyvitamin D3 in human prostate cancer and regulates apoptosis and the cell cycle in LNCaP prostate cancer cells.
    Myrthue A, Rademacher BL, Pittsenbarger J, Kutyba-Brooks B, Gantner M, Qian DZ, Beer TM.
    Clin Cancer Res; 2008 Jun 01; 14(11):3562-70. PubMed ID: 18519790
    [Abstract] [Full Text] [Related]

  • 5. Vitamin D3 analogs and their 24-oxo metabolites equally inhibit clonal proliferation of a variety of cancer cells but have differing molecular effects.
    Campbell MJ, Reddy GS, Koeffler HP.
    J Cell Biochem; 1997 Sep 01; 66(3):413-25. PubMed ID: 9257197
    [Abstract] [Full Text] [Related]

  • 6. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells.
    Murthy S, Agoulnik IU, Weigel NL.
    Prostate; 2005 Sep 01; 64(4):362-72. PubMed ID: 15754350
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The in vitro evaluation of 25-hydroxyvitamin D3 and 19-nor-1alpha,25-dihydroxyvitamin D2 as therapeutic agents for prostate cancer.
    Chen TC, Schwartz GG, Burnstein KL, Lokeshwar BL, Holick MF.
    Clin Cancer Res; 2000 Mar 01; 6(3):901-8. PubMed ID: 10741714
    [Abstract] [Full Text] [Related]

  • 9. 20-Cyclopropyl-cholecalciferol vitamin D3 analogs: a unique class of potent inhibitors of proliferation of human prostate, breast and myeloid leukemia cell lines.
    Koike M, Koshizuka K, Kawabata H, Yang R, Taub HE, Said J, Uskokovic M, Tsuruoka N, Koeffler HP.
    Anticancer Res; 1999 Mar 01; 19(3A):1689-97. PubMed ID: 10470102
    [Abstract] [Full Text] [Related]

  • 10. Effects of anti-EGFR antibody cetuximab on androgen-independent prostate cancer cells.
    Dhupkar P, Dowling M, Cengel K, Chen B.
    Anticancer Res; 2010 Jun 01; 30(6):1905-10. PubMed ID: 20651333
    [Abstract] [Full Text] [Related]

  • 11. Mechanism of antimitogenic action of vitamin D in human colon carcinoma cells: relevance for suppression of epidermal growth factor-stimulated cell growth.
    Tong WM, Hofer H, Ellinger A, Peterlik M, Cross HS.
    Oncol Res; 1999 Jun 01; 11(2):77-84. PubMed ID: 10489163
    [Abstract] [Full Text] [Related]

  • 12. 19-nor-26,27-bishomo-vitamin D3 analogs: a unique class of potent inhibitors of proliferation of prostate, breast, and hematopoietic cancer cells.
    Kubota T, Koshizuka K, Koike M, Uskokovic M, Miyoshi I, Koeffler HP.
    Cancer Res; 1998 Aug 01; 58(15):3370-5. PubMed ID: 9699668
    [Abstract] [Full Text] [Related]

  • 13. Growth inhibition, cell-cycle dysregulation, and induction of apoptosis by green tea constituent (-)-epigallocatechin-3-gallate in androgen-sensitive and androgen-insensitive human prostate carcinoma cells.
    Gupta S, Ahmad N, Nieminen AL, Mukhtar H.
    Toxicol Appl Pharmacol; 2000 Apr 01; 164(1):82-90. PubMed ID: 10739747
    [Abstract] [Full Text] [Related]

  • 14. [Synergistic inhibitory effect of all-trans retinoic acid and 1,25-dihydroxy vitamin D3 on growth of human hepatoma cell line HepG2].
    Lu HQ, Zheng J.
    Ai Zheng; 2006 Dec 01; 25(12):1470-6. PubMed ID: 17166369
    [Abstract] [Full Text] [Related]

  • 15. The human prostatic carcinoma cell line LNCaP expresses biologically active, specific receptors for 1 alpha,25-dihydroxyvitamin D3.
    Miller GJ, Stapleton GE, Ferrara JA, Lucia MS, Pfister S, Hedlund TE, Upadhya P.
    Cancer Res; 1992 Feb 01; 52(3):515-20. PubMed ID: 1370648
    [Abstract] [Full Text] [Related]

  • 16. Effect of combining anti-epidermal growth factor receptor antibody C225 and radiation on DU145 prostate cancer.
    Wagener M, Zhang X, Villarreal HG, Levy L, Allen P, Shentu S, Fang B, Krishnan S, Chang JY, Cheung MR.
    Oncol Rep; 2008 May 01; 19(5):1071-7. PubMed ID: 18425360
    [Abstract] [Full Text] [Related]

  • 17. 1Alpha,25dihydroxyvitamin D3 and platinum drugs act synergistically to inhibit the growth of prostate cancer cell lines.
    Moffatt KA, Johannes WU, Miller GJ.
    Clin Cancer Res; 1999 Mar 01; 5(3):695-703. PubMed ID: 10100724
    [Abstract] [Full Text] [Related]

  • 18. Combined cetuximab and genistein treatment shows additive anti-cancer effect on oral squamous cell carcinoma.
    Park SJ, Kim MJ, Kim YK, Kim SM, Park JY, Myoung H.
    Cancer Lett; 2010 Jun 01; 292(1):54-63. PubMed ID: 19959278
    [Abstract] [Full Text] [Related]

  • 19. Inhibition of angiogenesis by the antiepidermal growth factor receptor antibody ImClone C225 in androgen-independent prostate cancer growing orthotopically in nude mice.
    Karashima T, Sweeney P, Slaton JW, Kim SJ, Kedar D, Izawa JI, Fan Z, Pettaway C, Hicklin DJ, Shuin T, Dinney CP.
    Clin Cancer Res; 2002 May 01; 8(5):1253-64. PubMed ID: 12006546
    [Abstract] [Full Text] [Related]

  • 20. Anti-epidermal growth factor receptor monoclonal antibody 225 up-regulates p27KIP1 and induces G1 arrest in prostatic cancer cell line DU145.
    Peng D, Fan Z, Lu Y, DeBlasio T, Scher H, Mendelsohn J.
    Cancer Res; 1996 Aug 15; 56(16):3666-9. PubMed ID: 8706005
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 3.